Valeo Pharma (CSE: VPH-OTCQB: VPHIF) CEO Steve Saviuk and Ingenew Pharma CEO Pierre Laurin joined Steve Darling from Proactive to provide an update on what will be the role and involvement of Valeo in the Hesperco clinical program and clinical trial conducted by the Montreal Heart Institute.
Saviuk discusses that and also the availably to purchase Hesperco in North America and abroad. Laurin told Proactive about the benefits of Hesperidin and the origins of it.